Immunovant Sciences Gmbh
Clinical trials sponsored by Immunovant Sciences Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame lupus skin flares Results expected Oct 2026 (estimated)
- New drug aims to tame overactive thyroid without lifelong pills Results expected May 2027 (estimated)
- New shot could help when arthritis drugs fail Results expected Sep 2027 (estimated)
-
New drug batoclimab aims to ease muscle weakness in myasthenia gravis
Disease control Stopped earlyThis phase 3 trial tests batoclimab, a drug that blocks certain antibodies, in 240 adults with generalized myasthenia gravis (gMG). The study measures if batoclimab improves daily activities and muscle strength compared to a placebo. Participants receive injections weekly or bi-w…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for nerve disease: batoclimab safety trial expands
Disease control Stopped earlyThis study checks the long-term safety of a drug called batoclimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. About 108 people who finished an earlier batoclimab study will get weekly injections fo…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new antibody calm the immune attack in CIDP?
Disease control Stopped earlyThis trial is testing whether an experimental drug called batoclimab can help adults with active chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system damages nerves, causing weakness and disability. Participants receive either batoclimab o…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Batoclimab shows promise for thyroid eye disease in extension study
Disease control Stopped earlyThis study is for people who finished earlier trials of batoclimab for thyroid eye disease. It has two parts: one watches how long benefits last without treatment, and the other gives batoclimab to see if it helps more patients. The goal is to see if the drug can control eye bulg…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC